MedTrace Logo

Pilot Study to Establish a Repertoire of Megakaryocyte Markers, Quantifiable by Spectral Flow Cytometry, in Bone Marrow and Circulating in Patients Undergoing Cardiac Surgery for Bypass Grafting

NCT07026851 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-06-18

No results posted yet for this study

Summary

Megakaryopoiesis, the mechanism of blood platelet production, is difficult to assess in clinical practice as it relies solely on microscopic description. Recent studies described the presence of emergency megakaryopoiesis bypassing the classical maturation stages under certain conditions. Circulating megakaryocytes were identified in inflammatory and hemostatic conditions. The aim of this study is to characterize the phenotype of medullar and circulating megakaryocytes by flow cytometry during and after coronary artery bypass grafting.

Conditions

  • Cardiac Surgery for Bypass Grafting

Interventions

BIOLOGICAL

Blood and bone marrow sampling

This intervention involves the collection of peripheral blood before and 3 days after coronary artery bypass grafting (CABG), as well as a one-time collection of bone marrow sample during sternotomy. Samples are analyzed using spectral flow cytometry to characterize the phenotype and maturation stages of circulating and medullary megakaryocytes using a panel of specific surface antibodies.

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Agnès Ribes · Toulouse, Rangueil Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2027-07-31
Completion
2027-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07026851 on ClinicalTrials.gov